{"transactions":[{"id":865238,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-03T21:14:15.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":97256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":97256,"derivative":{"exercise_price":13.97,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":97256},"source":{"system":"sec-edgar","filing":"0001600620-26-000022","document":"wk-form4_1772572450.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000022/wk-form4_1772572450.xml","form_type":"4"}},{"id":865237,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:14:15.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":40761,"price":14.21,"value":579213.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":680299,"source":{"system":"sec-edgar","filing":"0001600620-26-000022","document":"wk-form4_1772572450.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000022/wk-form4_1772572450.xml","form_type":"4"}},{"id":865236,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:14:15.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":58160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."}],"balance_after":721060,"source":{"system":"sec-edgar","filing":"0001600620-26-000022","document":"wk-form4_1772572450.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000022/wk-form4_1772572450.xml","form_type":"4"}},{"id":887487,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:08:05.000Z","date":"2026-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":32901,"price":14.4,"value":473774.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":662900,"source":{"system":"sec-edgar","filing":"0001636642-26-000002","document":"wk-form4_1771880882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000163664226000002/wk-form4_1771880882.xml","form_type":"4"}},{"id":950024,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:12:08.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":42787,"price":15.95,"value":682452.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 30, 2025 and 1,457\ncommon shares were acquired on November 28, 2025."}],"balance_after":695801,"source":{"system":"sec-edgar","filing":"0001600620-26-000004","document":"wk-form4_1767647524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000004/wk-form4_1767647524.xml","form_type":"4"}},{"id":950023,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:12:08.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":54166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026."}],"balance_after":734631,"source":{"system":"sec-edgar","filing":"0001600620-26-000004","document":"wk-form4_1767647524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000004/wk-form4_1767647524.xml","form_type":"4"}},{"id":1226405,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-05T01:56:40.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":126416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":126416,"derivative":{"exercise_price":7.55,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":126416},"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1226404,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:56:40.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":58991,"price":7.92,"value":467208.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":680465,"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1226403,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:56:40.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":65902,"price":8,"value":527216.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":739456,"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1226402,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:56:40.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":135567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025."}],"balance_after":805358,"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1226401,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:56:40.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":82781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 31, 2024 and 438 common shares were acquired on November 29, 2024."}],"balance_after":669791,"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1588560,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Ops & Strategy"}}],"security":"Common Stock","published_at":"2024-03-07T21:43:47.000Z","date":"2024-03-06","kind":"sale","planned":false,"acquired":false,"shares":40665,"price":5.51,"value":224064.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 2, 2022 and March 2, 2023 grants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.475 to $5.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":584072,"source":{"system":"sec-edgar","filing":"0001600620-24-000036","document":"wk-form4_1709847815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000036/wk-form4_1709847815.xml","form_type":"4"}},{"id":1624612,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Ops & Strategy"}}],"security":"Common Stock","published_at":"2024-02-22T21:31:14.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":216666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 shares of common stock were acquired on May 31, 2023 and 2,430 shares of common stock were acquired on November 30, 2023."}],"balance_after":624737,"source":{"system":"sec-edgar","filing":"0001600620-24-000020","document":"wk-form4_1708637456.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000020/wk-form4_1708637456.xml","form_type":"4"}},{"id":1968230,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Ops & Strategy"}}],"security":"Common Stock","published_at":"2023-03-06T21:29:36.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":271134,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 271,134 newly awarded RSUs, 104,080 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 27,927 shares of common stock.  On March 2, 2023, 34,693 of Prior RSUs vested and 69,387 of Prior RSUs remained unvested."}],"balance_after":403141,"source":{"system":"sec-edgar","filing":"0001628280-23-006532","document":"wf-form4_167813816425740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023006532/wf-form4_167813816425740.xml","form_type":"4"}},{"id":2104901,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Ex VP, Internal Operations"}}],"security":"Common Stock","published_at":"2022-11-23T21:04:04.000Z","date":"2022-11-21","kind":"purchase","acquired":true,"shares":10000,"price":4.66,"value":46600.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,703 common stock of the Issuer acquired by the reporting person on May 31, 2022 pursuant to the Company's 2021 Employee Stock Purchase Plan."}],"balance_after":27927,"source":{"system":"sec-edgar","filing":"0001628280-22-030745","document":"wf-form4_166923742713580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022030745/wf-form4_166923742713580.xml","form_type":"4"}},{"id":2349613,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Ex VP, Intern'l Operations"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-04T21:12:47.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":178063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":178063,"derivative":{"exercise_price":12.01,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":178063},"source":{"system":"sec-edgar","filing":"0001628280-22-005129","document":"wf-form4_164642834162109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022005129/wf-form4_164642834162109.xml","form_type":"4"}},{"id":2349612,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Ex VP, Intern'l Operations"}}],"security":"Restricted Stock Unit","published_at":"2022-03-04T21:12:47.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":104080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date."}],"balance_after":104080,"derivative":{"underlying":"Common Shares","underlying_shares":104080},"source":{"system":"sec-edgar","filing":"0001628280-22-005129","document":"wf-form4_164642834162109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022005129/wf-form4_164642834162109.xml","form_type":"4"}},{"id":2349611,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Ex VP, Intern'l Operations"}}],"security":"Common Stock","published_at":"2022-03-04T21:12:47.000Z","date":"2022-03-02","kind":"sale","acquired":false,"shares":3052,"price":12.01,"value":36654.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards."}],"balance_after":16224,"source":{"system":"sec-edgar","filing":"0001628280-22-005129","document":"wf-form4_164642834162109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022005129/wf-form4_164642834162109.xml","form_type":"4"}},{"id":2349610,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Ex VP, Intern'l Operations"}}],"security":"Common Stock","published_at":"2022-03-04T21:12:47.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 18, 2021, the Reporting Person was granted stock based performance awards (\"Performance Awards\") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 876 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021."}],"balance_after":19276,"source":{"system":"sec-edgar","filing":"0001628280-22-005129","document":"wf-form4_164642834162109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022005129/wf-form4_164642834162109.xml","form_type":"4"}},{"id":2715834,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Ex VP, Intern'l Operations"}}],"security":"Common Stock","published_at":"2021-05-12T20:34:22.000Z","date":"2021-05-11","kind":"purchase","acquired":true,"shares":9900,"price":10.0746,"value":99738.54,"ownership":{"direct":true},"balance_after":9900,"source":{"system":"sec-edgar","filing":"0001628280-21-010023","document":"wf-form4_162085164781441.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021010023/wf-form4_162085164781441.xml","form_type":"4"}},{"id":4062249,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:54:52.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":101000,"price":6.15,"value":621150.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":11.85,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":101000},"source":{"system":"sec-edgar","filing":"0001171843-18-001107","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001107/formfour.xml","form_type":"4"}},{"id":4062248,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:54:52.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":75000,"price":4.2,"value":315000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":13.8,"expiration_date":"2026-03-02","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001171843-18-001107","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001107/formfour.xml","form_type":"4"}},{"id":4062247,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:54:52.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":28000,"price":3.18,"value":89040.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":14.82,"expiration_date":"2025-03-04","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001171843-18-001107","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001107/formfour.xml","form_type":"4"}},{"id":4062246,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:54:52.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":11.25,"value":281250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":6.75,"expiration_date":"2024-09-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001171843-18-001107","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001107/formfour.xml","form_type":"4"}},{"id":4062245,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:54:52.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":150000,"price":10.6,"value":1590000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":7.4,"expiration_date":"2024-06-09","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001171843-18-001107","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001107/formfour.xml","form_type":"4"}},{"id":4062244,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Common Stock, Class A","published_at":"2018-02-13T16:54:52.000Z","date":"2018-02-13","kind":"grant","acquired":false,"shares":36975,"price":18,"value":665550.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the \"Merger Agreement\")."}],"balance_after":36975,"source":{"system":"sec-edgar","filing":"0001171843-18-001107","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001107/formfour.xml","form_type":"4"}},{"id":4106824,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2018-01-04T17:15:38.000Z","date":"2017-12-31","kind":"grant","acquired":true,"shares":330,"price":9.1,"value":3003.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock."}],"balance_after":36975,"source":{"system":"sec-edgar","filing":"0001171843-18-000177","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318000177/formfour.xml","form_type":"4"}},{"id":4116873,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Common Stock, Class A","published_at":"2018-01-02T16:58:21.000Z","date":"2017-12-28","kind":"tax_withholding","acquired":false,"shares":19353,"price":17.98,"value":347966.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported represents the non-discretionary withholding of shares to satisfy the reporting person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units."},{"field":"shares","element":"transactionShares","label":"F2","text":"Common stock originally granted consists of restricted stocked units; this award was originally scheduled to vest on March 2, 2020, but was accelerated to vest on December 28, 2017."}],"balance_after":36645,"source":{"system":"sec-edgar","filing":"0001171843-18-000048","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318000048/formfour.xml","form_type":"4"}},{"id":4190816,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-10-05T16:37:22.000Z","date":"2017-09-30","kind":"grant","acquired":true,"shares":330,"price":9.1,"value":3003.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2017 through September 30, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock."}],"balance_after":2998,"source":{"system":"sec-edgar","filing":"0001171843-17-005958","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317005958/formfour.xml","form_type":"4"}},{"id":4260730,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-07-07T16:35:14.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":336,"price":8.93,"value":3000.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock."}],"balance_after":2668,"source":{"system":"sec-edgar","filing":"0001171843-17-004000","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317004000/formfour.xml","form_type":"4"}},{"id":4326370,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global HR, IT & Strategy"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-05-10T16:02:16.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":321,"price":9.35,"value":3001.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period January 1, 2017 through March 31, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the March 31, 2017 closing price of the issuer's common stock."}],"balance_after":2332,"source":{"system":"sec-edgar","filing":"0001171843-17-002918","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317002918/formfour.xml","form_type":"4"}},{"id":4394446,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Human Resources"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-03-08T17:01:43.000Z","date":"2017-03-06","kind":"grant","acquired":true,"shares":101000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest over a four-year period, with 25% vesting on March 2, 2018 and the remaining 75% vesting in equal monthly increments over the three-year period thereafter."}],"balance_after":379000,"derivative":{"exercise_price":11.85,"expiration_date":"2027-03-02","underlying":"Class A Common Stock","underlying_shares":101000},"source":{"system":"sec-edgar","filing":"0001171843-17-001361","document":"f4_donley030817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317001361/f4_donley030817.xml","form_type":"4"}},{"id":4394445,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Human Resources"}}],"security":"Common stock","published_at":"2017-03-08T17:01:43.000Z","date":"2017-03-06","kind":"grant","acquired":true,"shares":53000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock granted consists of restricted stock units that vest on March 2, 2020."}],"balance_after":53000,"source":{"system":"sec-edgar","filing":"0001171843-17-001361","document":"f4_donley030817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317001361/f4_donley030817.xml","form_type":"4"}},{"id":4496037,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec.VicePres,HumanResources"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-01-06T16:02:04.000Z","date":"2016-12-31","kind":"grant","acquired":true,"shares":286,"price":10.46,"value":2991.56,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the September 30, 2016 closing price of the issuer's common stock."}],"balance_after":2011,"source":{"system":"sec-edgar","filing":"0001171843-17-000123","document":"f4_donley010617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317000123/f4_donley010617.xml","form_type":"4"}},{"id":4576077,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec.VicePres,HumanResources"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2016-10-21T16:05:43.000Z","date":"2016-09-30","kind":"grant","acquired":true,"shares":320,"price":9.38,"value":3001.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2016 through September 30, 2016.  This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 1, 2016 closing price of the issuer's common stock."}],"balance_after":1725,"source":{"system":"sec-edgar","filing":"0001171843-16-012573","document":"f4_donley102116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184316012573/f4_donley102116.xml","form_type":"4"}}]}